Personalis, Inc. (PSNL) Operating Margin
- Operating margin · 12 months: Value -164.07%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -164.07% | Operating income / revenue. Period ending 2026-06-30. $-114.31M ÷ $69.67M × 100 ≈ -164.07% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -114.31M USD | Operating Income (Loss) |
| Revenue | 69.67M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 56.12M USD | Research and Development Expense |
| Selling, general and administration | 67.03M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-114.31M | $69.67M | (m) | $56.12M | $67.03M | -164.07% |
| 2026-03-31 | $-102.52M | $64.52M | (m) | $52.16M | $59.21M | -158.91% |
| 2025-12-31 | $-88.06M | $69.65M | (m) | $50.26M | $53.57M | -126.43% |
| 2025-09-30 | $-80.90M | $69.10M | (m) | $48.69M | $50.64M | -117.08% |
| 2025-06-30 | $-71.99M | $80.32M | (m) | $48.20M | $49.05M | -89.64% |
| 2025-03-31 | $-67.08M | $85.69M | (m) | $48.77M | $46.85M | -78.28% |
| 2024-12-31 | $-68.27M | $84.61M | (m) | $48.91M | $46.19M | -80.68% |
| 2024-09-30 | $-74.13M | $87.49M | (m) | $51.02M | $46.54M | -84.73% |
| 2024-06-30 | $-90.54M | $80.03M | (m) | $56.08M | $47.07M | -113.13% |
| 2024-03-31 | $-98.99M | $74.15M | (m) | $60.97M | $47.23M | -133.51% |
| 2023-12-31 | $-109.94M | $73.48M | (m) | $64.78M | $49.73M | -149.61% |
| 2023-09-30 | $-118.05M | $70.53M | (m) | $67.73M | $56.03M | -167.38% |
| 2023-06-30 | $-114.52M | $67.14M | (m) | $65.95M | $58.84M | -170.56% |
| 2023-03-31 | $-117.05M | $68.68M | (m) | $64.39M | $62.58M | -170.43% |
| 2022-12-31 | $-115.53M | $65.05M | (m) | $64.91M | $63.97M | -177.61% |
| 2022-09-30 | $-103.67M | $69.01M | (m) | $62.85M | $59.85M | -150.23% |
| 2022-06-30 | $-94.10M | $76.41M | (m) | $61.52M | $57.21M | -123.16% |
| 2022-03-31 | $-81.17M | $79.84M | (m) | $56.91M | $52.76M | -101.66% |
| 2021-12-31 | $-65.35M | $85.49M | (m) | $49.31M | $47.70M | -76.44% |
| 2021-09-30 | $-58.50M | $84.99M | (m) | $43.32M | $44.91M | -68.83% |
| 2021-06-30 | $-50.46M | $82.54M | (m) | $36.90M | $40.56M | -61.13% |
| 2021-03-31 | $-45.01M | $80.37M | (m) | $31.67M | $36.84M | -56.01% |
| 2020-12-31 | $-42.15M | $78.65M | (m) | $28.57M | $33.69M | -53.59% |
| 2020-09-30 | $-35.97M | $76.63M | (m) | $27.42M | $29.16M | -46.94% |
| 2020-06-30 | $-32.05M | $73.96M | (m) | $25.53M | $27.42M | -43.33% |
| 2020-03-31 | $-26.61M | $70.29M | (m) | $23.56M | $25.18M | -37.86% |
| 2019-12-31 | $-22.42M | $65.21M | (m) | $22.42M | $22.08M | -34.38% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $47.69M | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-13.77M | $37.77M | (m) | $14.30M | $11.27M | -36.45% |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-22.16M | $9.39M | (m) | $9.92M | $9.90M | -235.95% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |